Acepodia, a clinical-stage biotechnology company developing first-in-class cell therapies with its unique Antibody-Cell Conjugation (ACC) platform technology to address gaps in cancer care, today announced the appointments of Robin Andrulevich to the company’s Board of Directors and Eileen Higham, Ph.D., to the company’s Scientific Advisory Board.

Arthrosi Therapeutics, Inc., a clinical-stage biotech company announced results from its renal impairment studies and human AME study.

N/A

Arthrosi Therapeutics, Inc. welcomes Robert Thomas Keenan, MD, MPH, MBA, as Chief Medical Officer. Dr. Keenan has spent nearly 20 years in the field of rheumatology, bringing his vast expertise to the team as they reach Phase2b in the clinical development of the next generation molecule for the treatment of gout.

Maxpro Capital Acquisition Corp. (the “Company”), a Taiwan based SPAC, today announced the closing of its initial public offering (the “Offering”) of 9,000,000 units at $10.00 per unit.

Maxpro Capital Acquisition Corp. (the “Company”), a Taiwan based SPAC, announced today that it priced its initial public offering of $90 million, consisting of 9,000,000 units at $10.00 per unit.

N/A

 Acepodia, a clinical-stage biotechnology company developing first-in-class cell therapies with its unique Antibody-Cell Conjugation (ACC) platform technology to address gaps in cancer care, today reported new interim data from an ongoing Phase 1 dose escalation study demonstrating feasibility with ACE1702

Acepodia, a clinical-stage biotechnology company developing first-in-class cell therapies with its unique Antibody-Cell Conjugation (ACC) platform technology to address gaps in cancer care, today announced that it will present new interim data from an ongoing Phase 1 study (NCT04319757) evaluating ACE1702

N/A